TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10834766

Group type: EXPERIMENTAL
Intervention: Toddler‐Parent Psychotherapy (TPP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (women with no current or past mental disorder)
Number of subjects: 43
Study: 9166268

Group type: EXPERIMENTAL
Intervention: Closed in situ bypass technique
Number of subjects: 73

Group type: COMPARATOR
Intervention: Open in situ bypass technique
Number of subjects: 73
Study: 8471514

Group type: EXPERIMENTAL
Intervention: Coconut oil pre-irradiation application with PUVA (n = 14)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Coconut oil pre-irradiation application with narrow-band UVB phototherapy (n = 15)
Number of subjects: 29
Study: 3490972

Group type: EXPERIMENTAL
Intervention: ICI 35,868
Number of subjects: 10
Study: 2661966

Group type: EXPERIMENTAL
Intervention: oral cyclical combination of estradiol valerate and cyproterone acetate
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: percutaneous 17 beta‐estradiol, supplemented by oral progesterone during the second year
Number of subjects: 110

Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 110

Group type: COMPARATOR
Intervention: percutaneous placebo cream
Number of subjects: 110
Study: 31138727

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atezolizumab-chemotherapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atezolizumab-bevacizumab-chemotherapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nivolumab-ipilimumab
Number of subjects: 7
Study: 31753429

Group type: COMPARATOR
Intervention: CPVI (Circumferential Pulmonary Vein Isolation)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: POBI (Posterior wall Box Isolation)
Number of subjects: 217

Group type: COMPARATOR
Intervention: CPVI
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: POBI
Number of subjects: 217
Study: 28365464

Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy (MGT)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Treatment as usual (TAU), mainly individual-based cognitive behavioural therapy (CBT)
Number of subjects: 215
Study: 25335446

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation with ferrous sulfate
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 188
Study: 23232827

Group type: EXPERIMENTAL
Intervention: Early steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Late steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 7)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (saline drops)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Early steroid
Number of subjects: 42
Study: 21177664

Group type: EXPERIMENTAL
Intervention: The11 injury prevention programme applied during each practice session throughout the 2009-10 season
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group continued practice sessions as usual
Number of subjects: 0
Study: 19487710

Group type: COMPARATOR
Intervention: No hormone therapy suspension (n = 567)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: 1 month hormone therapy suspension (n = 570)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: 2 months hormone therapy suspension (n = 567)
Number of subjects: 1704
Study: 17557039

Group type: COMPARATOR
Intervention: Topical mesalazine alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined treatment with mesalazine plus symbiotic (zir fos)
Number of subjects: 24
Study: 14765315

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (50 units delivered via two 25-U injections of 0.25 ml each into the pancreatic sphincter)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham saline injection (0.50 ml of saline injected into the duodenal lumen)
Number of subjects: 26
Study: 11232021

Group type: COMPARATOR
Intervention: Highly purified FSH (75 IU FSH/ampoule; group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (75 IU FSH and 75 IU LH/ampoule; group B)
Number of subjects: 50
Study: 9744493

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Tamoxifen and HRT
Number of subjects: 1117
Study: 8299896

Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 305

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 305
Study: 2467327

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Corynebacterium parvum (C. parvum)
Number of subjects: 58
Study: 5557537

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Syntocinon (Oxytocin)
Number of subjects: 15
Study: 28539526

Group type: EXPERIMENTAL
Intervention: LM25
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: LM50
Number of subjects: 172
Study: 25962753

Group type: EXPERIMENTAL
Intervention: Clinical Leadership in Aged Care (CLiAC) program for middle managers
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 503
Study: 23477625

Group type: EXPERIMENTAL
Intervention: PCI at hospitals without on-site cardiac surgery
Number of subjects: 3691

Group type: COMPARATOR
Intervention: PCI at hospitals with on-site cardiac surgery
Number of subjects: 3691
Study: 21667437

Group type: EXPERIMENTAL
Intervention: Increased energy intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 19801024

Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) alone
Number of subjects: 264

Group type: COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) plus Optimal Medical Therapy (OMT)
Number of subjects: 264
Study: 16749414

Group type: EXPERIMENTAL
Intervention: 3% desflurane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1% sevoflurane
Number of subjects: 75

Group type: COMPARATOR
Intervention: Epidural anaesthesia with ropivacaine
Number of subjects: 75
Study: 15121136

Group type: EXPERIMENTAL
Intervention: Overnight switch to oxcarbazepine monotherapy
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Progressive switch to oxcarbazepine monotherapy
Number of subjects: 286
Study: 11887980

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptives
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Progestagen-only preparations (150 microg desogestrel)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Levonorgestrel-containing oral contraceptives
Number of subjects: 86
Study: 9783333

Group type: EXPERIMENTAL
Intervention: 1.5 mg dexamethasone once a day for 4 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8148710

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing glucose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing rice
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing glycine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Carbohydrate free solution
Number of subjects: 45
Study: 3061561

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin, gentamicin and metronidazole (AGM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: AGM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study: 31344054

Group type: EXPERIMENTAL
Intervention: Effective contraceptive methods (defined as those with rates of unintended pregnancy of less than 10 per 100 women in first year of typical use)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Missed opportunities for family planning counseling
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Counseling addressing health concerns about modern contraception
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Consideration of starting modern contraceptive methods
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Availability of short and long acting reversible contraceptive methods
Number of subjects: 849
Study: 28833829

Group type: EXPERIMENTAL
Intervention: 18 F‐FDG‐PET‐guided dose painting (DPBC or DPBN)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 18 F‐FDG‐PET-guided dose painting (DPBC or DPBN)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional IMRT
Number of subjects: 144
Study: 25518997

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MIM brackets
Number of subjects: 30
Study: 24116857

Group type: EXPERIMENTAL
Intervention: Antimicrobial surgical gloves
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-antimicrobial surgical gloves
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of antimicrobial vs non-antimicrobial gloves
Number of subjects: 14
Study: 21823283

Group type: EXPERIMENTAL
Intervention: Acupoint injection desensitization with autoblood (AJA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medicine group (Dexamethasone Acetate cream and Setastine Hydrochloride)
Number of subjects: 200
Study: 20126852

Group type: EXPERIMENTAL
Intervention: Nebido
Number of subjects: 32

Group type: COMPARATOR
Intervention: Deposteron
Number of subjects: 32

Group type: COMPARATOR
Intervention: Durateston
Number of subjects: 32
Study: 17958029

Group type: EXPERIMENTAL
Intervention: DPP-IV resistant GLP-1 analogues (e.g., exenatide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitors (gliptins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin (first DPP-IV inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer-acting GLP-1 mimetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15266329

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment (5-year duration)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (hormone-receptor-negative tumours, no further therapy)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced ovarian dysfunction (amenorrhoea)
Number of subjects: 146
Study: 11589750

Group type: EXPERIMENTAL
Intervention: 85% formic acid application
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 100
Study: 9036866

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection in men younger than 60 years
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection in older age group
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (age- and locality-matched)
Number of subjects: 230
Study: 7931480

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) administered by continuous infusion (CIV) at a maximum-tolerated dose (MTD) of 8 mg/m2 bolus plus 10 mg/m2/d for 4 days (total dose per cycle, 48 mg/m2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) at different dose levels (DL)
Number of subjects: 64
Study: 3126220

Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 4 mg three times a day
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 30841807

Group type: EXPERIMENTAL
Intervention: 0.05% BAC
Number of subjects: 108

Group type: COMPARATOR
Intervention: 0.10% BAC
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 27720142

Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring and pharmacist management
Number of subjects: 351

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 351
Study: 24269362

Group type: EXPERIMENTAL
Intervention: Radial access in high-volume centers
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Radial access in intermediate-volume centers
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Radial access in low-volume centers
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Overall percutaneous coronary intervention volume
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Radial center volume
Number of subjects: 7021

Group type: EXPERIMENTAL
Intervention: Femoral center volume
Number of subjects: 7021
Study: 22717726

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 45 mg kg(‐1) in 100 ml of isotonic saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 20047523

Group type: EXPERIMENTAL
Intervention: Dental care during pregnancy
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Perceived oral health
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Importance of healthy teeth for baby vs self
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Gingival bleeding before and during pregnancy
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Cost as a deterrent for dental visits
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Dental care visits for gingival bleeding during pregnancy
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Perception of oral health
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Relationship between gingival bleeding and perceived oral health
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Factors related to gingival bleeding during pregnancy
Number of subjects: 649
Study: 18655982

Group type: EXPERIMENTAL
Intervention: AcrySof IQ SN60WF IOL
Number of subjects: 65

Group type: COMPARATOR
Intervention: AcrySof SA60AT IOL
Number of subjects: 65
Study: 15994252

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no CPAP treatment)
Number of subjects: 18
Study: 12905750

Group type: EXPERIMENTAL
Intervention: 2 g propacetamol in 100 ml normal saline intravenously
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50 mg dolantin intramuscularly
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.6 g mannitose in 100 ml NS intravenously as placebo control to propacetamol
Number of subjects: 40
Study: 10227267

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8913990

Group type: EXPERIMENTAL
Intervention: Group A (moderate dose of alcohol 0.56 g/kg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Group AC (moderate dose of alcohol 0.56 g/kg with expectancy challenge)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Group NT (no treatment, no alcohol)
Number of subjects: 66
Study: 1487552

Group type: EXPERIMENTAL
Intervention: Pyrazinoylguanidine (PZG) 600 mg twice daily for 4 weeks
Number of subjects: 12
Study: 3897960

Group type: EXPERIMENTAL
Intervention: Cefoxitin (30 mg/kg intravenously over 30 minutes, one hour before surgery, and 30 mg/kg over one hour, 3 hours, and 6 hours after initial infusion)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no routine intra or postoperative antibiotics)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 30577943

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for depressed adolescents (IPT‐A) with a week 4 decision point
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy for depressed adolescents (IPT‐A) with a week 8 decision point
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increased frequency of IPT‐A (twice per week)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Addition of fluoxetine
Number of subjects: 40
Study: 29388275

Group type: EXPERIMENTAL
Intervention: 150 min·wk‐1 of aerobic exercise (low-dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 300 min·wk‐1 of aerobic exercise (high-dose)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 39
Study: 25218903

Group type: EXPERIMENTAL
Intervention: Ozone preconditioning (Major Auto-Hemotherapy, 35µg/ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n=50, age and gender matched)
Number of subjects: 50
Study: 22151583

Group type: EXPERIMENTAL
Intervention: Timeline follow-back (TLFB) self-report of cannabis use
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Timeline follow-back (TLFB) self-report of cannabis use with 19 days cut-off
Number of subjects: 103
Study: 22945778

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lubricant gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 96
Study: 16636770

Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 271

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 271
Study: 15929619

Group type: EXPERIMENTAL
Intervention: Echo Off Line program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard videotape echocardiography
Number of subjects: 56
Study: 11899180

Group type: EXPERIMENTAL
Intervention: Stented C‐E pericardial valve (CE)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Toronto Stentless Porcine valve (SPV)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Both groups (CE and SPV)
Number of subjects: 99
Study: 10450276

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (mean dose = 57.9 mg/day, duration = mean 20.3 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (mean dose = 57.9 mg/day)
Number of subjects: 20
Study: 7771886

Group type: EXPERIMENTAL
Intervention: Inoue technique
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Double balloon technique
Number of subjects: 262

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 262
Study: 2589137

Group type: EXPERIMENTAL
Intervention: Abstinence from smoking for 24 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonsmokers (control group)
Number of subjects: 16
Study: 31302276

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP) in improved prone position (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Percutaneous vertebroplasty (PVP) in right lateral position (group B)
Number of subjects: 60
Study: 27660153

Group type: EXPERIMENTAL
Intervention: Quality of Dying and Death (QODD) assessed by family members in the Netherlands
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Quality of Dying and Death (QODD) assessed by family members in the United States
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Quality of Dying and Death (QODD) assessed by nurses in the Netherlands
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Quality of Dying and Death (QODD) assessed by nurses in the United States
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Quality of Dying and Death (QODD) total score assessed by nurses in the Netherlands
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Quality of Dying and Death (QODD) total score assessed by nurses in the United States
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Comparison of nurse-assessed QODD items between the Netherlands and the United States
Number of subjects: 446
Study: 25293586

Group type: EXPERIMENTAL
Intervention: Weight Loss Maintenance (LM)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Weight Loss Regain (LR)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Weight Stable (WS)
Number of subjects: 138
Study: 24474991

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 320
Study: 21465003

Group type: EXPERIMENTAL
Intervention: Light cola (EL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Light cola plus abrasion (EAL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Regular cola (ER)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Regular cola plus abrasion (EAR)
Number of subjects: 10
Study: 17934156

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) delivered through the V.A.C. Therapy System (n = 77)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard moist wound therapy (MWT) (n = 85)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 162
Study: 16503775

Group type: EXPERIMENTAL
Intervention: Topical cyclosporin 0.05%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobramycin 0.3%/dexamethasone 0.1%
Number of subjects: 0
Study: 14517597

Group type: EXPERIMENTAL
Intervention: Oral risedronate 5 mg/day for 12 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: No risedronate (Control group)
Number of subjects: 34
Study: 10711621

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with a poly(lactic acid)‐based bioabsorbable membrane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 12
Study: 9353575

Group type: EXPERIMENTAL
Intervention: Low-calorie/low-fat diet (LCFD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-calorie/high-fat diet (HCFD)
Number of subjects: 8
Study: 8401337

Group type: EXPERIMENTAL
Intervention: Enzyme Allergo‐Sorbent Testing (EAST)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Skin tests
Number of subjects: 97
Study: 3018068

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (30 ml of 2.39 M, 6.17 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aluminum-magnesium antacid (30 ml equivalent to 71.7 mmol of in vitro buffer)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 31414887

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CCRG) using ERICA software
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional cognitive rehabilitation (TCRG)
Number of subjects: 40
Study: 30096139

Group type: EXPERIMENTAL
Intervention: PopART universal-test-and-treat (UTT) package delivered by community HIV care providers (CHiPs)
Number of subjects: 120272
Study: 26250076

Group type: EXPERIMENTAL
Intervention: Minimum intervention (test group)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 254
Study: 24256079

Group type: EXPERIMENTAL
Intervention: Immediate surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 39
Study: 22375574

Group type: EXPERIMENTAL
Intervention: Small changes weight loss program (3-month intervention with bi-weekly phone calls for 6 months)
Number of subjects: 25